IRadimed Stock Discussion

The company's President and CEO, Roger Susi, expressed satisfaction with the Q4 2023 preliminary results, highlighting the growing demand for their products and the continued record revenues.

IRadimed is perceived positively due to its growing ROCE and the ability to profitably reinvest capital, which has also started to reap benefits for its shareholders. Regardless of the promising performance, further due diligence is recommended for the company.